129-Xe MRI Study of Single Triple Therapy Inhaler Effects in COPD Patients With Moderate-severe Dyspnea and/or Poor Health Status With High or Low Risk of Exacerbation

• Status: NOT_YET_RECRUITING
• Trial end date: 2027-10-01

Summary

The goal of this study is to study how 12-weeks daily (and optional 48-weeks) single inhaler triple therapy (fluticasone furoate (FF)-an inhaled corticosteroid; umeclidinium (UMEC)-a long-acting muscarinic antagonist; vilanterol (VI)-a long-acting 2-adrenergic agonist) works to treat adults with COPD. The investigators will compare the effects of this medication on adults with COPD who are at low risk of a flare-up and adults with COPD who are at high risk of a flare-up. The main questions it aims to answer are:

• Does FF/UMEC/VI improve ventilation defect percent as measured on 129-Xenon MRI in adults with moderate-severe COPD
• Evaluate the relationships between the ventilation defect percent and lung function test results

Participants will:

• Take the inhaler FF/UMEC/VI once daily for 12-weeks (optional 48-weeks)
• visit Robarts 2 times (with optional 3rd visit) for tests and imaging

• Phase: PHASE4

Details

• Lead Sponsor: Western University, Canada